Cover Image
Market Research Report

Global MEK Inhibitors Market 2019-2023

Published by TechNavio (Infiniti Research Ltd.) Product code 905977
Published Content info 136 Pages
Delivery time: 1-2 business days
Price
Back to Top
Global MEK Inhibitors Market 2019-2023
Published: August 6, 2019 Content info: 136 Pages
Description

About this market

MEK is a drug that inhibits the mitogen-activated extracellular signal-regulated kinase. Technavio's MEK inhibitors market analysis considers sale from MEKINIST, COTELLIC, and MEKTOVI. Our analysis also considers the MEK inhibitors in Asia, Europe, North America, and ROW. In 2018, the MEKINIST segment had a significant share, and this trend is expected to continue over the forecast period. Factors such as treatment of melanoma, presence of protein kinase, and cellular proliferation will play a significant role in the MEKINIST segment to maintain its market position. Also, our global MEK inhibitors market report looks at factors such as high target affinity and specificity of MEK inhibitors, use of combination therapies, and strategic alliances. However, the uncertainties in abundance of substitutes, adverse effects of MEK inhibitors and stringent regulations may hamper the growth MEK inhibitors market over the forecast period.

Overview

High target affinity and specificity of MEK inhibitors

MEK inhibitors are the small molecule targeted therapy drugs that are used for the treatment of carcinomas. These drugs act on MEK directly and hinder its activity and help in decreasing the growth of the tumor. This demand for high target affinity and specificity of MEK inhibitors will lead to the expansion of the global MEK inhibitors market at a CAGR of over 8% during the forecast period.

Use of protein biomarkers in the diagnosis of NSCLC

Protein biomarkers help in detecting tumors as they can differentiate between the morphological as well as the chemical features of the protein in normal cells and abnormal cells. A major factor that is increasing the popularity of protein biomarkers for the detection of NSCLC is their efficacy in the diagnosis of the condition. The use of predictive protein biomarkers can also lower the cost of treatment as well as the adverse effects associated with it. This development is expected to have a positive impact on the overall market growth.

For the detailed list of factors that will drive the global MEK inhibitors market during the forecast period 2019-2023, view our report.

Competitive Landscape

With the presence of a few major players, global MEK inhibitors market is concentrated. Technavio's robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading MEK inhibitors manufacturers, that include AstraZeneca Plc, F. Hoffmann-La Roche Ltd., Novartis AG, Ono Pharmaceutical Co. Ltd., Pfizer Inc.

Also, global MEK inhibitors, market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage on all forthcoming growth opportunities.

Table of Contents
Product Code: IRTNTR31830

TABLE OF CONTENTS

PART 01: EXECUTIVE SUMMARY

PART 02: SCOPE OF THE REPORT

  • 2.1 Preface
  • 2.2 Preface
  • 2.3 Currency conversion rates for US$

PART 03: MARKET LANDSCAPE

  • Market ecosystem
  • Market characteristics
  • Market segmentation analysis

PART 04: MARKET SIZING

  • Market definition
  • Market sizing 2018
  • Market size and forecast 2018-2023

PART 05: FIVE FORCES ANALYSIS

  • Bargaining power of buyers
  • Bargaining power of suppliers
  • Threat of new entrants
  • Threat of substitutes
  • Threat of rivalry
  • Market condition

PART 06: MARKET SEGMENTATION BY PRODUCT

  • Market segmentation by product
  • Comparison by product
  • MEKINIST - Market size and forecast 2018-2023
  • COTELLIC - Market size and forecast 2018-2023
  • MEKTOVI - Market size and forecast 2018-2023
  • Market opportunity by product

PART 07: CUSTOMER LANDSCAPE

PART 08: GEOGRAPHIC LANDSCAPE

  • Geographic segmentation
  • Geographic comparison
  • North America - Market size and forecast 2018-2023
  • Europe - Market size and forecast 2018-2023
  • Asia - Market size and forecast 2018-2023
  • ROW - Market size and forecast 2018-2023
  • Key leading countries
  • Market opportunity

PART 09: DECISION FRAMEWORK

PART 10: DRIVERS AND CHALLENGES

  • Market drivers
  • Market challenges

PART 11: MARKET TRENDS

  • Special drug designations
  • Expanded application
  • Use of protein biomarkers in diagnosis of NSCLC

PART 12: VENDOR LANDSCAPE

  • Overview
  • Landscape disruption
  • Competitive scenario

PART 13: VENDOR ANALYSIS

  • Vendors covered
  • Vendor classification
  • Market positioning of vendors
  • AstraZeneca Plc
  • F. Hoffmann-La Roche Ltd.
  • Novartis AG
  • Ono Pharmaceutical Co. Ltd.
  • Pfizer Inc.

PART 14: APPENDIX

  • Research methodology
  • List of abbreviations
  • Definition of market positioning of vendors

PART 15: EXPLORE TECHNAVIO

  • Exhibit 01: Product overview
  • Exhibit 02: Global pharmaceuticals market
  • Exhibit 03: Segments of global pharmaceuticals market
  • Exhibit 04: Market characteristics
  • Exhibit 05: Market segments
  • Exhibit 06: Market definition - Inclusions and exclusions checklist
  • Exhibit 07: Market size 2018
  • Exhibit 08: Global market: Size and forecast 2018-2023 ($ millions)
  • Exhibit 09: Global market: Year-over-year growth 2019-2023 (%)
  • Exhibit 10: Five forces analysis 2018
  • Exhibit 11: Five forces analysis 2023
  • Exhibit 12: Bargaining power of buyers
  • Exhibit 13: Bargaining power of suppliers
  • Exhibit 14: Threat of new entrants
  • Exhibit 15: Threat of substitutes
  • Exhibit 16: Threat of rivalry
  • Exhibit 17: Market condition - Five forces 2018
  • Exhibit 18: Product - Market share 2018-2023 (%)
  • Exhibit 19: Comparison by product
  • Exhibit 20: MEKINIST - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 21: MEKINIST - Year-over-year growth 2019-2023 (%)
  • Exhibit 22: COTELLIC - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 23: COTELLIC - Year-over-year growth 2019-2023 (%)
  • Exhibit 24: MEKTOVI - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 25: MEKTOVI - Year-over-year growth 2019-2023 (%)
  • Exhibit 26: Market opportunity by product
  • Exhibit 27: Customer landscape
  • Exhibit 28: Market share by geography 2018-2023 (%)
  • Exhibit 29: Geographic comparison
  • Exhibit 30: North America - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 31: North America - Year-over-year growth 2019-2023 (%)
  • Exhibit 32: Top 3 countries in North America
  • Exhibit 33: Europe - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 34: Country-wise age-standardized rate of melanomas in Europe 2018
  • Exhibit 35: Country-wise prevalence rate of NSCLC in Europe 2008
  • Exhibit 36: Europe - Year-over-year growth 2019-2023 (%)
  • Exhibit 37: Top 3 countries in Europe
  • Exhibit 38: Asia - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 39: Asia - Year-over-year growth 2019-2023 (%)
  • Exhibit 40: Top 3 countries in Asia
  • Exhibit 41: ROW - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 42: ROW - Year-over-year growth 2019-2023 (%)
  • Exhibit 43: Top 3 countries in ROW
  • Exhibit 44: Key leading countries
  • Exhibit 45: Market opportunity
  • Exhibit 46: Alternative therapies based on MEK inhibitors for various oncology indications
  • Exhibit 47: Side effects of MEK and BRAF inhibitors
  • Exhibit 48: Impact of drivers and challenges
  • Exhibit 49: Drug designations
  • Exhibit 50: Vendor landscape
  • Exhibit 51: Landscape disruption
  • Exhibit 52: Vendors covered
  • Exhibit 53: Vendor classification
  • Exhibit 54: Market positioning of vendors
  • Exhibit 55: AstraZeneca Plc - Vendor overview
  • Exhibit 56: AstraZeneca Plc - Business segments
  • Exhibit 57: AstraZeneca Plc - Organizational developments
  • Exhibit 58: AstraZeneca Plc - Geographic focus
  • Exhibit 59: AstraZeneca Plc - Key offerings
  • Exhibit 60: AstraZeneca Plc - Key customers
  • Exhibit 61: F. Hoffmann-La Roche Ltd. - Vendor overview
  • Exhibit 62: F. Hoffmann-La Roche Ltd. - Business segments
  • Exhibit 63: F. Hoffmann-La Roche Ltd. - Organizational developments
  • Exhibit 64: F. Hoffmann-La Roche Ltd. - Geographic focus
  • Exhibit 65: F. Hoffmann-La Roche Ltd. - Segment focus
  • Exhibit 66: F. Hoffmann-La Roche Ltd. - Key offerings
  • Exhibit 67: F. Hoffmann-La Roche Ltd. - Key customers
  • Exhibit 68: Novartis AG - Vendor overview
  • Exhibit 69: Novartis AG - Business segments
  • Exhibit 70: Novartis AG - Organizational developments
  • Exhibit 71: Novartis AG - Geographic focus
  • Exhibit 72: Novartis AG - Segment focus
  • Exhibit 73: Novartis AG - Key offerings
  • Exhibit 74: Novartis AG - Key customers
  • Exhibit 75: Ono Pharmaceutical Co. Ltd. - Vendor overview
  • Exhibit 76: Ono Pharmaceutical Co. Ltd. - Business segments
  • Exhibit 77: Ono Pharmaceutical Co. Ltd. - Organizational developments
  • Exhibit 78: Ono Pharmaceutical Co. Ltd. - Geographic focus
  • Exhibit 79: Ono Pharmaceutical Co. Ltd. - Key offerings
  • Exhibit 80: Ono Pharmaceutical Co. Ltd. - Key customers
  • Exhibit 81: Pfizer Inc. - Vendor overview
  • Exhibit 82: Pfizer Inc. - Business segments
  • Exhibit 83: Pfizer Inc. - Organizational developments
  • Exhibit 84: Pfizer Inc. - Geographic focus
  • Exhibit 85: Pfizer Inc. - Segment focus
  • Exhibit 86: Pfizer Inc. - Key offerings
  • Exhibit 87: Pfizer Inc. - Key customers
  • Exhibit 88: Validation techniques employed for market sizing
  • Exhibit 89: Definition of market positioning of vendors
Back to Top